Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
X
Share Page
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts

Press Release

Printer Friendly Version View printer-friendly version
<< Back
vTv Therapeutics to Present Two Posters at the American Diabetes Association’s 77th Scientific Sessions

HIGH POINT, N.C.--(BUSINESS WIRE)--Jun. 8, 2017-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced that Company management will present two posters featuring vTv Therapeutics’ orally administered, non-peptide GLP-1R agonist at the American Diabetes Association’s 77th Scientific Sessions held in San Diego, California, June 9 – 13, 2017.

Details of the presentations are listed below:

Late-Breaking Poster title: “Is Less More? Learning to Dose the Oral, Non-peptide GLP-1R Agonist, TTP273 in Type 2 Diabetics”
Poster Number: 168-LB
Category: 12-E Clinical Therapeutics/New Technology–Oral Agents
Date and Time: Sunday, June 11, 2017, 12 - 1:00pm PT
Location: Hall B

Poster title: “TTP273, Oral (Non-peptide) GLP-1R Agonist: Improved Glycemic Control without Nausea and Vomiting in Phase 2”
Poster number: 1220-P
Category: 12-E Clinical Therapeutics/New Technology–Oral Agents
Date and Time: Sunday, June 11, 2017, 12 - 1:00pm PT
Location: Hall B

“We look forward to providing an update on TTP273, one of vTv’s lead diabetes compounds, at the American Diabetes Association’s 77th Scientific Sessions,” said Carmen Valcarce, Ph.D., executive vice president, chief scientific officer, vTv Therapeutics. “We remain focused on our goal of bringing forward both TTP273 and TTP399, vTv’s glucokinase activator, and continue to pursue opportunities with potential partners, including companies based outside the U.S. We are confident that we will find the right partner to support the continued development of these investigational therapies, which we believe could offer new options to patients with this disease.”

About TTP273

TTP273 is an investigational, orally dosed small molecule that works by activating the GLP-1 receptor. Activation of the GLP-1 receptor leads to the enhancement of insulin secretion and suppression of glucagon production and decreased food intake. There are currently several marketed injectable GLP-1 therapies. These agents have demonstrated notable glucose lowering in addition to weight loss; however, their widespread use may be hindered by the route of administration (injection) and by the high incidence of gastrointestinal side effects (nausea and vomiting).

About Type 2 Diabetes

Type 2 diabetes is a result of the body’s inability to use insulin properly to control sugar in the bloodstream. Type 2 diabetes represents up to 95% of diabetes patients, imposing a growing burden on healthcare systems globally. Diabetes remains the 7th leading cause of death in the United States, costing the healthcare system $245 billion annually. According to the American Diabetes Association, there are 29.1 million Americans, or 9.3% of the population, living with diabetes.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

Forward-Looking Statements

This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.

Source: vTv Therapeutics Inc.

Investors:
vTv Therapeutics Inc.
Michael Gibralter, 646-378-2938
IR@vtvtherapeutics.com
or
Media:
Pure Communications Inc.
Katie Engleman, 910-509-3977
Katie@purecommunicationsinc.com